Genelux CORP Form 4 insider transactions

Yong Yu, Chief Scientific Officer of GENELUX Corp, sold 653 shares of common stock on August 4, 2026 for $2.94 per share.

Joseph Cappello, Chief Technical Officer of GENELUX Corp, sold 653 shares of common stock on August 4, 2026 for $2.95 per share.

Thomas Zindrick, President and CEO of GENELUX Corp, sold 3,023 shares of common stock on August 4, 2026 for $2.95 per share.

John W. Smither, a Director at GENELUX Corp, reported a sale of 12,000 common shares on July 1, 2026, for tax coverage purposes.

GENELUX Corp. Chief Financial Officer Matthew Pulisic acquired 278,906 shares of common stock through restricted stock units.

Genelux Corp reports the grant of restricted stock units to General Counsel Eric Groen, with vesting scheduled over four years.

Genelux Corp's Chief Technical Officer, Joseph Cappello, acquired 174,841 restricted stock units (RSUs) under the company's 2022 Equity Incentive Plan.

Genelux Corp director James L. Tyree acquired 28,409 shares of common stock and 31,566 stock options, as detailed in a Form 4 filing.

Genelux Corp. CEO Thomas Zindrick acquired restricted stock units and additional shares, increasing his beneficial ownership of the company.

Genelux Corp director Thomas John acquired restricted stock units and stock options, indicating continued investment and potential future equity.

Genelux Corp Director Mary Mirabelli acquired restricted stock units and stock options, increasing her beneficial ownership.

Genelux Corp reports that Chief Scientific Officer Yu Yong acquired 119,318 restricted stock units (RSUs) on June 16, 2026, as part of the company's 2022 Equity Incentive Plan.

GENELUX Corp reports that Director John W. Smither acquired restricted stock units and stock options on June 16, 2026, as detailed in a Form 4 filing.

Ralph Smalling, Head of Regulatory at Genelux Corp, sold 192 shares of common stock to cover tax liabilities related to RSU vesting.

Director Thomas John sold 10,000 shares of Genelux Corporation common stock at an average price of $2.9801.

Genelux Corporation Chief Scientific Officer Yong Yu sold 605 shares of common stock to cover tax liabilities related to restricted stock unit vesting.

Genelux Corporation Chief Technical Officer Joseph Cappello sold 605 shares of common stock to satisfy tax obligations related to RSU vesting.

Genelux Corporation President and CEO Thomas Zindrick sold 2,798 shares of common stock to satisfy tax obligations related to restricted stock unit vesting.

Ralph Smalling, Head of Regulatory at Genelux Corporation, sold 270 shares of common stock to cover tax liabilities related to RSU vesting.

Genelux's Head of Regulatory, Ralph Smalling, sold a total of 585 common shares across two transactions to cover tax liabilities related to restricted stock unit vesting.

GENELUX Chief Technical Officer Joseph Cappello sold 906 shares of common stock to cover tax obligations related to restricted stock unit vesting.

Genelux Corporation's SVP of Clinical Development, Yu Yong, sold 906 shares of common stock to cover tax liabilities from restricted stock unit vesting.

Genelux Corporation's President and CEO, Thomas Zindrick, sold 3,582 shares of common stock to cover tax liabilities related to restricted stock unit vesting.

A director at Genelux Corp. sold 10,000 shares of common stock for $2.8957 per share under a pre-arranged 10b5-1 trading plan.

Genelux Corporation's Chief Medical Officer, Jason Litten, was granted 275,000 stock options with an exercise price of $4.55, vesting over four years.

Genelux Corporation's SVP of Clinical Development, Yu Yong, sold common stock in two transactions to cover tax liabilities related to restricted stock unit vesting.

Genelux CEO Thomas Zindrick sold shares in pre-planned transactions to cover tax liabilities from restricted stock unit vesting.

Genelux Corporation's Chief Technical Officer, Joseph Cappello, sold common stock on multiple dates to cover tax liabilities associated with restricted stock unit vesting.

Genelux Corporation's Head of Regulatory, Ralph Smalling, sold common stock on multiple dates in 2025 to cover tax liabilities related to restricted stock unit vesting.

Genelux Corporation Director Thomas John sold 10,000 shares of common stock for a weighted average price of $5.0008 per share on December 1, 2025, under a pre-arranged 10b5-1 trading plan.